NCCM
LCTX icon

Nine Chapters Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Nine Chapters Capital Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-65,037
Closed -$196K – 118
2017
Q1 		$196K Buy
+65,037
New +$185K 0.26% 163

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Nine Chapters Capital Management's LCTX Position: Q2 2017 in Review

Nine Chapters Capital Management sold out of Lineage Cell Therapeutics (LCTX) in Q2 2017, closing a stake of 65,037 shares — an estimated $196K sold.

Nine Chapters Capital Management first reported a position in LCTX in Q1 2017 and held it in 1 quarter. The position peaked at $196K in Q1 2017. 109 funds tracked by Wall St. Rank hold LCTX as of Q2 2017.

  • Nine Chapters Capital Management reported no remaining Lineage Cell Therapeutics position as of Q2 2017 after selling out during the quarter.
  • Nine Chapters Capital Management sold 65,037 Lineage Cell Therapeutics shares in Q2 2017, an estimated $196K.
  • Nine Chapters Capital Management first reported a position in Lineage Cell Therapeutics in Q1 2017 and held it in 1 quarter.
  • Nine Chapters Capital Management's Lineage Cell Therapeutics position peaked at $196K in Q1 2017.
  • 109 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2017.

Based on Nine Chapters Capital Management's 13F filing for Q2 2017, filed 31 Jul 2017.